bosentan anhydrous has been researched along with Pulmonary Arterial Hypertension in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 27 (84.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PL; Chen, YH; Fu, L; Fu, WH; He, WJ; Jiang, Q; Liu, CL; Ma, R; Ren, N; Shen, Y; Wang, T; Wang, XN; Xia, JL; Zhang, NF | 1 |
| Teksin, ZS; Timur, B; Usta, DY | 1 |
| Alotaibi, M; Fernandes, TM; Hoang, HB; Kim, NH; Lombardi, S; Papamatheakis, DG; Poch, DS; Rodriguez, C; Wu, S; Yang, JZ | 1 |
| Ceriani, F; Cosentino, M; De Ponti, R; Ferrari, M; Imporzani, A; Lattanzio, M; Marino, F; Martini, S | 1 |
| Gorbachevsky, SV; Shmalts, AA | 2 |
| Ekhlasi, M; Majd, ZK; Peiravian, F; Sheikhi, S; Yousefi, N | 1 |
| Kuno, T; Matsuzaki, Y; Shirasu, T; Sumitomo, N; Takagi, H; Watanabe, A; Watanabe, H; Watanabe, K; Yasuhara, J | 1 |
| Dwivedi, J; Jain, P; Jain, S; Jaiswal, S; Kumawat, J; Panchal, J; Sharma, A; Sharma, S; Verma, K | 1 |
| Sakao, S; Tanabe, N; Tatsumi, K | 1 |
| Locatelli, I; Petrovič, M | 1 |
| Betancourt-Montoya, M; Corona-Villalobos, C | 1 |
| Jiang, X; Jing, ZC; Xu, XQ | 1 |
| Natali, S; Palmieri, M; Polidori, C | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Alehan, D; Aykan, H; Aypar, E; Ertugrul, İ; Karagöz, T | 1 |
| Emoto, N; Hatae, T; Horibata, S; Kumagai, S; Nakayama, K; Suzuki, Y; Tsuji, G; Uemura, Y; Yorifuji, K | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Amiya, E; Hara, T; Hatano, M; Hosoya, Y; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Morita, H; Saito, A; Tsuji, M; Yao, A | 1 |
| Chen, Z; Deng, X; Li, W; Peng, Y; Wang, Y; Xiao, Y; Xiao, Z; Zeng, Y | 1 |
| Kang, JH; Kim, DW; Kim, JY; Kwon, YB; Lee, HJ; Oh, DW; Park, CW; Park, ES; Rhee, YS; Shin, DH | 1 |
| Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Aleevskaya, AM; Martynyuk, TV | 1 |
| Afra, F; Mehri, M; Namazi, S | 1 |
| Chen, C; Chen, J; Chen, T; Chen, Y; Liu, M; Zheng, B; Zheng, H | 1 |
| Cai, Z; Guo, A; Kong, Q; Liu, X; Wang, M; Zhao, C; Zhao, H | 1 |
| Chen, J; Guo, N; Parks, D; Tian, Z; Zhao, Q | 1 |
| Dudek, K; Gajek, J; Jankowska-Polańska, B; Jonas, K; Kopeć, G; Sarzyńska, K; Świątoniowska-Lonc, N | 1 |
| Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N | 1 |
| Bonnet, D; Dahdah, N; Ferguson-Sells, L; Landry, J; Li, B; Small, D | 1 |
| Coons, JC; Kido, K | 1 |
12 review(s) available for bosentan anhydrous and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
[Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Treatment Outcome | 2022 |
Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension | 2022 |
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Network Meta-Analysis; Pulmonary Arterial Hypertension; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2023 |
Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Topics: Bosentan; Disease Progression; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Circulation; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Pyrazoles; Pyrimidines; Sildenafil Citrate; Treatment Failure; Vascular Remodeling; Vasoconstriction | 2019 |
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Bayes Theorem; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Exercise; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hemodynamics; HIV Infections; Humans; Observational Studies as Topic; Pulmonary Arterial Hypertension | 2021 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Russia; Sildenafil Citrate | 2020 |
Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
Topics: Bosentan; Child; Cost-Benefit Analysis; Humans; Hypertension, Pulmonary; Pharmaceutical Preparations; Pulmonary Arterial Hypertension; Quality of Life; Sildenafil Citrate | 2021 |
Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Liver Function Tests; Network Meta-Analysis; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Randomized Controlled Trials as Topic; Walk Test | 2022 |
Quality of life of patients with pulmonary arterial hypertension: a meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Humans; Iloprost; Pulmonary Arterial Hypertension; Quality of Life; Surveys and Questionnaires | 2021 |
Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
Topics: Bosentan; Endothelin Receptor Antagonists; Heart Diseases; Hemodynamics; Humans; Pulmonary Arterial Hypertension; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2019 |
2 trial(s) available for bosentan anhydrous and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Topics: Adult; Area Under Curve; Body Weight; Bosentan; Child; Female; Humans; Male; Pulmonary Arterial Hypertension; Tadalafil | 2022 |
Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study.
Topics: Adolescent; Antihypertensive Agents; Area Under Curve; Bosentan; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Tadalafil | 2019 |
18 other study(ies) available for bosentan anhydrous and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Formulation development, optimization by Box-Behnken design, characterization, in vitro, ex-vivo, and in vivo evaluation of bosentan-loaded self-nanoemulsifying drug delivery system: A novel alternative dosage form for pulmonary arterial hypertension trea
Topics: Administration, Oral; Animals; Biological Availability; Bosentan; Drug Delivery Systems; Emulsions; Nanoparticles; Particle Size; Pulmonary Arterial Hypertension; Rats; Rats, Wistar; Solubility; Surface-Active Agents; Tablets | 2022 |
Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report.
Topics: Bosentan; Counseling; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Arterial Hypertension; Receptors, Epoprostenol; Transaminases | 2022 |
[Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Randomized Controlled Trials as Topic; Vasodilator Agents | 2021 |
Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
Topics: Bosentan; Cost-Effectiveness Analysis; Humans; Hypertension, Pulmonary; Iran; Pulmonary Arterial Hypertension; Quality of Life | 2023 |
Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Molecular Docking Simulation; Pulmonary Arterial Hypertension; Rats; Sulfonamides | 2023 |
From an innocent heart murmur to pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Child, Preschool; Female; Heart Defects, Congenital; Heart Murmurs; Humans; Oximetry; Pulmonary Arterial Hypertension; Truncus Arteriosus, Persistent | 2019 |
The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS).
Topics: Academies and Institutes; Administration, Inhalation; Angioplasty, Balloon; Antihypertensive Agents; Asian People; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Cardiology; Cooperative Behavior; Endothelin Receptor Antagonists; Female; Growth Differentiation Factor 2; Guidelines as Topic; Humans; Iloprost; Mutation; Phenylpropionates; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pulmonary Medicine; Pyridazines; Takayasu Arteritis; Vasodilator Agents | 2019 |
Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cost Savings; Drug Costs; Drugs, Generic; Female; Humans; Italy; Male; Middle Aged; Pharmacy Service, Hospital; Prevalence; Pulmonary Arterial Hypertension | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Endothelin A Receptor Antagonists; Female; Humans; Male; Prospective Studies; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Time Factors; Treatment Outcome; Walk Test; Young Adult | 2020 |
Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Bosentan; Carbohydrate Sulfotransferases; Chemical and Drug Induced Liver Injury; Creatinine; Endothelin Receptor Antagonists; Female; Humans; Japan; Liver; Male; Models, Statistical; Mutation; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pulmonary Arterial Hypertension; Risk Assessment; Sulfotransferases | 2020 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Adult; Aged; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Japan; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Placebos; Prostaglandins I; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyridazines; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance | 2020 |
Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report.
Topics: Aftercare; Antihypertensive Agents; Bosentan; Cardiomegaly; Child, Preschool; Combined Modality Therapy; Echocardiography; Humans; Hypersplenism; Ligation; Male; Portal Vein; Pulmonary Arterial Hypertension; Radiography, Thoracic; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vascular Malformations; Vascular Resistance; Vasodilator Agents | 2020 |
Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Topics: Administration, Inhalation; Animals; Bosentan; Dry Powder Inhalers; Monocrotaline; Particle Size; Pulmonary Arterial Hypertension; Rats | 2021 |
[Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrimidines; Retrospective Studies; Russia; Sulfonamides; Treatment Outcome | 2020 |
Bosentan-induced immune hemolytic anemia in 17 years old man. A case report.
Topics: Adolescent; Anemia, Hemolytic; Antihypertensive Agents; Bosentan; Humans; Male; Prednisolone; Pulmonary Arterial Hypertension | 2021 |
The Influence of Bosentan on MicroRNA-27a/PPARγ/ET-1 Signaling Pathway in Pulmonary Artery Hypertension.
Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Humans; MicroRNAs; PPAR gamma; Pulmonary Arterial Hypertension; Signal Transduction | 2021 |